Author Archives for Atlanpole Biotherapies

Clean Cells opened its capital to ArchiMed to support its growth strategy in the biopharmaceutical sector

21 January 2019

The biopharmaceutical services company Clean Cells, specialized in biosafety testing and cell bank and virus seed stock production, has reached... View Article

Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus

21 January 2019

EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS GAITHERSBURG, Md. and... View Article

Telix Pharmaceuticals Completes Acquisition of Atlab Pharma

21 January 2019

Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced the completion of the acquisition of Atlab Pharma SAS (“Atlab”). The option... View Article

Samabriva and Affilogic entered into an Option and License Agreement to develop Nanofitin®-conjugated biotherapeutics to treat Lysosomal Storage Disorders

21 January 2019

Amiens, France, and Nantes, France, September 10, 2018 – Samabriva and Affilogic jointly announced that they recently entered into an... View Article

In-Cell-Art results with two Top 10 Pharma will be presented at the 16th Annual Discovery on Target on September 25-28 2018 in Boston

21 January 2019

In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article

In-Cell-Art, the Institut Pasteur and BioNet-Asia announce the collaborative development of a dengue vaccine candidate successful in preclinical study

21 January 2019

Nantes – Paris – France, 19th of June, 2018 – In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies, BioNet-Asia... View Article

Bioregate Forum 2018 #2nd edition

21 January 2019

Bioregate Forum is the “must attend” European gathering for key players in the Regenerative Medicine sector: 3 days dedicated to... View Article

Affilogic is financing a proof of concept thanks to the Boost4Health programme

21 January 2019

Affilogic,a member of Atlanpole Biotherapies, has received a € 5000 voucher as part of the Boost4Health programme. This support has... View Article

A thymic cell study programme for developing an ambitious transplant strategy

21 January 2019

This programme is led by Dr. Matthieu Giraud, a specialist in immunology, genetics and bioinformatics. Having spent a number of... View Article

In-Cell-Art announces a contract with one of top 5 Global Pharmas to discover potential antibodies medicines

21 January 2019

Nantes – France, 24 of May , 2018 – In-Cell-Art (ICA), a member of Atlanpole Biotherapies, a biotechnology company specialized in... View Article